Diurnal Limited, A Neurocrine Biosciences Company, Presents Phase 3 Extension Study Data For Modified-Release Hydrocortisone In Patients With Congenital Adrenal Hyperplasia At ENDO 2023
Portfolio Pulse from Benzinga Newsdesk
Diurnal Limited, a Neurocrine Biosciences company, presented Phase 3 extension study data for modified-release hydrocortisone in patients with congenital adrenal hyperplasia at ENDO 2023.

June 15, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences' subsidiary Diurnal Limited presented positive Phase 3 extension study data for modified-release hydrocortisone in patients with congenital adrenal hyperplasia.
The positive Phase 3 extension study data for modified-release hydrocortisone, developed by Diurnal Limited, a subsidiary of Neurocrine Biosciences, is likely to have a positive short-term impact on the stock price of Neurocrine Biosciences (NBIX). The successful presentation at ENDO 2023 indicates progress in the development of the drug, which could potentially lead to regulatory approval and commercialization, benefiting the company's revenues and growth prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100